Specialty drugs dominate FDA approvals
Clinical trials involving specialty drugs continue to emerge along the pipeline as there is an increased desire for directed therapy.
Drug approvals in recent years have revealed a transforming pharmaceutical environment, shifting away from traditional drug therapies to a steady trend of complex specialty treatments for chronic diseases such as cancer, inflammatory diseases, multiple sclerosis, hepatitis C and HIV.
According to a report on medical cost trends by PricewaterhouseCoopers Health Research Institute, 21% of the new drugs approved by the FDA in 2005 were specialty drugs. That percentage jumped to more than 50% of new drugs as specialty treatments in 2012, and the number is expected to reach 60% in 2014.